Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study.
http://www.medilexicon.com/medicalnews.php?newsid=265633
http://www.medilexicon.com/medicalnews.php?newsid=265633
No comments:
Post a Comment